This is a prospective exploratory biodistribution study in patients with interstitial lung
disease (ILD).
The purpose of this research study is to determine where and to which degree the FAPI tracer
(68Ga-FAPI-46) accumulates in normal and fibrotic lung tissues of patients with interstitial
lung disease.
The study will include patients with interstitial lung disease with fibrotic lesions who are
scheduled to undergo lung biopsy or transplantation.
The study will include 30 patients, the upper limit for PET imaging studies conducted under
the Radioactive Drug Research Committee (RDRC) purview.
Participants will be injected with up to 7 mCi of 68-GaFAPi and will undergo one PET/CT scan.
The study is sponsored by Ahmanson Translational Theranostic Division at UCLA.